Navigation Links
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
Date:12/10/2008

BRISBANE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today said that it will report top-line results in January 2009 from its Phase 1b clinical trial of protease inhibitor ITMN-191 (R7227) in combination with standard-of-care Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) for 14 days of treatment in treatment-naive patients chronically infected with the hepatitis C virus (HCV) genotype 1. ITMN-191 is being developed in collaboration with Roche.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "We now expect to report top-line data from six dosage cohorts; three cohorts each of twice-daily and three-times-daily regimens. Although the 14-day triple combination study remains blinded at this time, and thus only limited inferences regarding safety can be made, adverse events to date have generally been mild to moderate and there have been no discontinuations during the study. Results from this study have guided the design of our planned Phase 2 program which is anticipated to begin in the first half of 2009."

Mr. Welch continued, "In addition, we are pleased to report that the first dosage cohort has been enrolled in the INFORM-1 study of ITMN-191 in combination with polymerase inhibitor R7128 (Roche/Pharmasset). INFORM-1 is the first ever study to investigate the combined effects of two direct antiviral agents in the absence of interferon in treatment-naive HCV patients. We expect results of this study to be reported at a major medical conference in the first half of 2009."

Phase 1b Triple Combination Trial Design

The Phase 1b randomized, double-blind, placebo-controlled, 14-day triple combination study in treatment-naive patients chronically infected with HCV genotype 1 was designed to inform the dose selection and study de
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... WASHINGTON , Sept. 19, 2014 /PRNewswire-USNewswire/ ... often used to inflate sales of brand drugs ... Part D,  according to a new report ... Services Office of the Inspector General (OIG). Federal anti-kickback ... sales of goods that are subsidized by the ...
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 ... Market Outlook to 2020″, provides key ... General Surgery devices market. The report ... dollars, and volume (in units) within ... Cystoscopes, Colonoscopes, Sigmoidoscopes, Esophagoscopes & Gastroscopes, ...
(Date:9/19/2014)... September 19, 2014 According ... Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise ... Advanced technologies - Global Forecast to 2019" published ... to reach $19,786.3 Million by 2019 from $14,240.0 ... from 2014 to 2019. Browse 74 ...
Breaking Medicine Technology:PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... data presented today at the Society for Cardiovascular ... first to look at the use of highly ... detect restricted blood flow to the heart in ... Preliminary results from the ST-DETECT Trial using high-fidelity ...
... a compression clothing distributor, recently added three new ... Medical, Solaris and Gottfried are now available online through ... are used in lymphedema treatment. Lymphedema is a medical ... hands. Although it can be caused by a genetic ...
Cached Medicine Technology:New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 2New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 3BrightLife Direct Introduces 3 New Lymphedema Product Lines 2
(Date:9/19/2014)... NH 9/18/14) A leading Dartmouth researcher, working with The ... a paper published today in the Journal of ... increase the risk of melanoma. , "For the first ... length of these telomeres play a part in the ... study Mark Iles, PhD, School of Medicine at the ...
(Date:9/19/2014)... September 19, 2014 According to a ... the embattled blood-thinner Xarelto, named as defendants in several ... Pleas, have moved the court to dismiss those suits ... have sufficient connection with Philadelphia.* The cases include, for ... (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), which was ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- U.S. military troops deployed ... skin cancer, according to a new study. ... researchers revealed. In some cases, military personnel developed blisters ... color, shape or size of their moles since being ... risk factors for skin cancer, the study authors noted. ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- The U.S. Food and ... on Thursday. Trulicity is part of a class of once-a-week ... with type 2 diabetes. "Trulicity is a new ... existing treatment regimens to control blood sugar levels in the ... director of the FDA,s Office of Drug Evaluation II, said ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... associated with additional injury leading to structural and ... The injury induced during reperfusion is evolved a ... upon reoxygenation and a delayed phase. It is ... induces a cascade of series of cellular events ...
... blood clots are often recommended to stop these medications ... However, interruption of these medications can place patients at ... by Shai Friedland at the VA Palo Alto hospital ... without interrupting anticoagulation. Their study will be published on ...
... continuity after gastric resection. It seems that insufficient attention ... conditions affect the gastroduodenal system after distal gastric resection. ... duodenal suture dehiscence, but still many pathological mechanisms involved ... research article to be published on April 28, 2009 ...
... several other institutions worldwide, have pinpointed for the first ... endemic and epidemic mosquito-borne illness that is a rapidly ... The study, published in the May issue of ... the direct and indirect costs of dengue cases in ...
... Work, Money and the EconomySeven out of 10 ... 7 Economic pressures are having an increasing ... to a new survey by the American Psychological ... reporting significant stress related to work, money, housing ...
... of Directors of Tyco International Ltd. (NYSE: TYC ... (CHF) per share, payable on August 26, 2009, to shareholders ... 2009, subject to a required filing with the Swiss Commercial ... second installment of an annual dividend of CHF 0.93 per ...
Cached Medicine News:Health News:A new light on the mechanisms of early stage liver reperfusion injury 2Health News:Dengue fever costs billions in health care, lost productivity and absenteeism 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 3
Inquire...
... Used for the injection of contrast ... The dual lumen design eliminates the need ... designed to promote atraumatic passage into and ... layer of hydrophilic polymer that when activated, ...
Used for retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Medicine Products: